他拉唑帕利联合阿昔替尼治疗晚期透明细胞肾细胞癌的1b/2期研究
这项1b/2期研究评估他拉唑帕利联合阿昔替尼在难治性透明细胞肾细胞癌中的安全性和抗肿瘤活性,采用3+3剂量递增后扩展队列设计。2020至2023年共入组23例患者,确定的2期推荐剂量为他拉唑帕利每日1 mg联合阿昔替尼5 mg每日两次。联合方案显示安全性,但未达到预设的继续评估疗效阈值。
要点
- 2期推荐剂量为他拉唑帕利每日1 mg联合阿昔替尼5 mg每日两次。
- 中位无进展生存期为6.1个月(95%CI 3.5-8.4)。
- 13例(56%)发生至少1次≥3级治疗中出现的不良事件。
核心结论
- 该联合方案显示出安全性,但未达到预设的继续评估疗效阈值。
- 这是首个关于VEGFR靶向酪氨酸激酶抑制剂联合PARP抑制剂治疗透明细胞肾细胞癌的报告。
研究设计与样本
- 1b/2期研究,采用3+3设计进行他拉唑帕利剂量递增联合固定标准剂量阿昔替尼,随后在独立队列中进行剂量扩展。
- 2020至2023年共入组23例透明细胞肾细胞癌患者,其中剂量递增队列15例,剂量扩展队列8例。
- 主要终点为确定2期推荐剂量和客观缓解率。
主要发现
- 2期推荐剂量为他拉唑帕利每日1 mg联合阿昔替尼5 mg每日两次。
- 在2期推荐剂量下,14例患者中有13例因疾病进展停止治疗。
- 中位无进展生存期为6.1个月(95%CI 3.5-8.4)。
- 13例(56%)患者发生至少1次≥3级治疗中出现的不良事件,9例(39%)发生至少1次治疗相关≥3级不良事件,最常见为腹泻、恶心和贫血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inactivation of the VHL gene leads to HIF accumulation, angiogenesis, and genomic instability. In this phase 1b/2 study, we assessed the safety and antitumor activity of axitinib combined with talazoparib in treatment-refractory clear-cell renal cell carcinoma (ccRCC). Patients received escalating doses of talazoparib with a fixed standard dose of axitinib in a 3 + 3 design. This was followed by a dose expansion phase in a separate cohort. The primary endpoints were determination of the recommended phase 2 dose (RP2D) and the objective response rate. From 2020 to 2023, 23 patients with ccRCC were enrolled: 15 in the dose escalation cohort and eight in the dose expansion cohort. The RP2D was identified as talazoparib 1 mg daily with axitinib 5 mg twice daily. At the RP2D, 13/14 patients discontinued treatment because of disease progression. Median progression-free survival was 6.1 mo (95% confidence interval 3.5-8.4). Thirteen patients (56%) experienced at least one grade 3+ treatment-emergent adverse event (AE), while nine (39%) experienced at least one treatment-related grade ≥3 AE, of which diarrhea, nausea, and anemia were the most common. This is the first report on a VEGFR-targeted tyrosine kinase inhibitor combined with a PARP inhibitor for ccRCC. While our results demonstrate the safety of this strategy, the combination did not meet a predefined efficacy threshold for continued evaluation. This trial is registered on Clinicaltrials.gov as NCT04337970.
引用
- Kotecha RR, Doshi SD, Knezevic A, et al. A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma. Eur Urol Oncol. 2025. PMID: 40158923. doi:10.1016/j.euo.2025.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。